Involving Gene Duplication Within The Cell (e.g., Amplification, Co-amplification, Etc.) Patents (Class 435/464)
-
Patent number: 9371512Abstract: The present invention relates to a permanent human cell line comprising a nucleic acid sequence for the adenoviral gene functions E1A and E1B and the nucleic acid sequence for the SV40 large T-antigen or the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1). Further, the present invention relates to a method for transient expression of recombinant polypeptides and proteins in said permanent human cell line.Type: GrantFiled: February 5, 2010Date of Patent: June 21, 2016Assignee: CEVEC PHARMACEUTICALS GMBHInventors: Gudrun Schiedner, Christoph Volpers
-
Patent number: 8993327Abstract: Systems and methods are described for parallel macromolecular delivery and biochemical/electrochemical interface to whole cells employing carbon nanostructures including nanofibers and nanotubes. A method includes providing a first material on at least a first portion of a first surface of a first tip of a first elongated carbon nanostructure; providing a second material on at least a second portion of a second surface of a second tip of a second elongated carbon nanostructure, the second elongated carbon nanostructure coupled to, and substantially parallel to, the first elongated carbon nanostructure; and penetrating a boundary of a biological sample with at least one member selected from the group consisting of the first tip and the second tip.Type: GrantFiled: April 7, 2003Date of Patent: March 31, 2015Assignee: UT-Battelle, LLCInventors: Timothy E. McKnight, Anatoli V. Melechko, Guy D. Griffin, Michael A. Guillorn, Vladimir L. Merkulov, Michael L. Simpson
-
Production of modified fatty acids in plants through rDNA targeted integration of heterologous genes
Patent number: 8546645Abstract: The present invention relates to transgenic plants comprising a plurality of nucleic acids heterologous to said plant, each of said nucleic acid comprising a coding sequence operably linked to one or more regulatory elements for directing expression of said coding sequence in said plant, said nucleic acid being stably integrated at or adjacent to rDNA sequences, or a seed, organ, tissue, part or cell thereof, or a descendant of said plant, seed, organ, tissue, part or cell; methods of producing the transgenic plants; and methods of producing oil using the transgenic plants.Type: GrantFiled: September 30, 2009Date of Patent: October 1, 2013Assignee: Agrisoma Biosciences Inc.Inventors: Steven Fabijanski, Michael Lindenbaum, Ping Fu, Elizabeth-France Marillia -
Patent number: 8217222Abstract: A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression.Type: GrantFiled: September 29, 2006Date of Patent: July 10, 2012Assignees: Anticancer, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Mingxu Xu, Yuying Tan, Levy Kopelovich
-
Publication number: 20120064631Abstract: The present invention provides novel means for amplifying a target gene outside a chromosome of the mammalian cell with a high probability in amplifying a target gene with use of IR/MAR plasmid, to further improve a high-level gene amplification system. The present invention is a method of amplifying a target gene outside a chromosome of a mammalian cell, and includes the step of transferring, concurrently to a mammalian cell, (i) a vector including (a) a mammalian replication initiation region functioning in a mammalian cell and (b) a nuclear matrix attachment region functioning in a mammalian cell, (ii) a target gene, and (iii) a polynucleotide including a telomere repetitive sequence.Type: ApplicationFiled: March 24, 2010Publication date: March 15, 2012Applicant: HIROSHIMA UNIVERSITYInventor: Noriaki Shimizu
-
Patent number: 8076138Abstract: The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.Type: GrantFiled: October 15, 2009Date of Patent: December 13, 2011Assignee: Codexis Mayflower Holdings, LLCInventors: Stephen DelCardayre, Matthew B. Tobin, Willem P. C. Stemmer, Jon E. Ness, Jeremy S. Minshull, Phillip A. Patten, Venkiteswatan Mani Subramanian, Linda A. Castle, Claus M. Krebber, Steven H. Bass, Ying-Xin Zhang, Anthony R. Cox, Gjalt W. Huisman, Ling Yuan, Joseph A. Affholter
-
Patent number: 7629170Abstract: The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.Type: GrantFiled: August 17, 2006Date of Patent: December 8, 2009Assignee: Maxygen, Inc.Inventors: Stephen delCardayre, Matthew B. Tobin, Willem P. C. Stemmer, Jon E. Ness, Jeremy S. Minshull, Phillip A. Patten, Venkiteswatan Mani Subramanian, Linda A. Castle, Claus M. Krebber, Steven H. Bass, Ying-Xin Zhang, Anthony R. Cox, Gjalt W. Huisman, Ling Yuan, Joseph A. Affholter
-
Publication number: 20080153167Abstract: The invention is directed to methods for in vivo amplification of neural progenitor cells using the proliferative environment of glial neoplasms in adult brain. The progenitor cells have the capacity to proliferate and differentiate into mature brain cells which can be used for cell replacement therapies. The invention also provides cell replacement therapy methods for treating central nervous system diseases or injuries, including multiple sclerosis, stroke, Alzheimer's disease and Parkinson's disease.Type: ApplicationFiled: June 21, 2007Publication date: June 26, 2008Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Peter Canoll, James Goldman, Marcela Assanah, Sanja Ivkovic
-
Patent number: 7294500Abstract: The invention relates to Infectious Bursal Disease Virus (“IBDV”) and vaccines therefor. Provided are infectious recombinant Infectious Bursal Disease Virus (“rIBDV”) essentially incapable of growing in a cell that is not derived from a bursa cell, or an infectious rIBDV having retained at least part of the very virulent characteristics of a very virulent Infectious Bursal Disease Virus (“vvIBDV”).Type: GrantFiled: January 14, 2002Date of Patent: November 13, 2007Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Hendrik Johannis Boot, Anna Agnes H. M. ter Huurne, Bernardus Petrus H. Peeters
-
Publication number: 20020150997Abstract: The invention relates to &agr;-galactosidase and to polynucleotides encoding the &agr;-galactosidase. In addition methods of designing new &agr;-galactosidases and method of use thereof are also provided. The &agr;-galactosidases have increased activity and stability at increased pH and temperature.Type: ApplicationFiled: March 29, 2002Publication date: October 17, 2002Applicant: Diversa CorporationInventors: Jay M. Short, Dennis Murphy, John Reid, Eric J. Mathur
-
Patent number: 6444441Abstract: The invention concerns a process for the production of muteins of eukaryotic polypeptides in eukaryotic cells by means of homologous recombination. The invention additionally concerns a process for the production of human cells which are suitable for the production of human mutated proteins. Finally the invention concerns the human cells produced by the process and mutated human proteins obtainable therefrom as well as pharmaceutical preparations which contain these muteins.Type: GrantFiled: January 21, 2000Date of Patent: September 3, 2002Assignee: Roche Diagnostics GmbHInventors: Anne Stern, Konrad Honold
-
Publication number: 20020090717Abstract: Novel cell lines useful for trans-complementing E1-deleted adenoviral vectors are described. The cell lines are capable of providing high yields of E1-deleted adenoviral vectors in the absence of replication-competent adenovirus over multiple passages.Type: ApplicationFiled: January 16, 2002Publication date: July 11, 2002Applicant: The Trustees of the University of PennsylvaniaInventors: Guangping Gao, James M. Wilson
-
Patent number: 6365394Abstract: Novel cell lines useful for trans-complementing E1-deleted adenoviral vectors are described. The cell lines are capable of providing high yields of E1-deleted adenoviral vectors in the absence of replication-competent adenovirus over multiple passages.Type: GrantFiled: September 11, 2000Date of Patent: April 2, 2002Assignee: The Trustees of the University of PennsylvaniaInventors: Guangping Gao, James M. Wilson
-
Patent number: 6080575Abstract: The invention relates to a nucleic acid construct for expressing an active substance which is activated by an enzyme which is released from mammalian cells, which construct comprises the following components: a) at least one promoter element, b) at least one DNA sequence which encodes an active compound (protein B) c) a least one DNA sequence which encodes an amino acid sequence (part structure C) which can be cleaved specifically by an enzyme which is released from a mammalian cell, and d) at least one DNA sequence which encodes a peptide or protein (part structure D) which is bound to the active compound (protein B) by way of the cleavable amino acid sequence (part structure C) and inhibits the activity of the active compound (protein B), and also to the use of the nucleic acid construct for preparing a drug for treating diseases.Type: GrantFiled: January 16, 1998Date of Patent: June 27, 2000Assignee: Hoechst Aktiengesellschaft AGInventors: Hans Heinrich Heidtmann, Rolf Mueller, Hans-Harald Sedlacek
-
Patent number: 6069296Abstract: Disclosed is substantially pure DNA encoding a C. elegans Egl-10 polypeptide; substantially pure Egl-10 polypeptide; methods of obtaining RGS encoding DNA and RGS polypeptides; and methods of using the RGS DNA and RGS polypeptides to regulate G-protein signalling.Type: GrantFiled: June 2, 1995Date of Patent: May 30, 2000Assignee: Massachusetts Institute of TechnologyInventors: H. Robert Horvitz, Michael Koelle
-
Patent number: 5981214Abstract: Methods and compositions are provided for expression of mammalian genes in culture. An amplifiable gene is introduced by homologous recombination in juxtaposition to a target gene, the resulting combination of amplifiable gene and target gene transferred to a convenient host and the target gene amplified by means of the amplifiable gene. The resulting expression host may then be grown in culture with enhanced expression of the target gene.Type: GrantFiled: June 6, 1995Date of Patent: November 9, 1999Assignee: Cell Genesys, Inc.Inventor: Arthur I. Skoultchi
-
Patent number: 5976833Abstract: The object of the present invention is to provide a method for improving productivity in the production of useful substances by animal cells. The present invention discloses a method for animal cell culture to produce a desired substance, comprising the steps of (1) culturing animal cells at a temperature at which the animal cells can grow; and (2) culturing the animal cells at a lower temperature.Type: GrantFiled: September 19, 1996Date of Patent: November 2, 1999Assignee: Suntory LimitedInventors: Kazuaki Furukawa, Kazuhiro Ohsuye